February 22, 2019 01:31 PM EST

Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity”

John Carroll

Editor & Founder

Karyopharm’s attempt to gain an accelerated approved for selinexor as a treatment for drug-resistant cases of multiple myeloma is in serious jeopardy. And investors know …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity”

John Carroll

Editor & Founder

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Karyopharm shares tank af­ter FDA in­sid­ers slam their case on the ef­fi­ca­cy of a can­cer drug with “sig­nif­i­cant tox­i­c­i­ty”

Editor & Founder

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity”